NEW YORK, June 26, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO), a Nasdaq-listed global shipping and logistics company, proudly acknowledges the recent correspondence from President Donald J. Trump in response to a letter submitted by Mr. Brian B. Su, the Company's Independent Director and Chairman of the Compensation Committee. In his letter dated June 18, 2025, President Trump expressed appreciation for Mr. Su's views on restoring American strength on the world stage and reaffirmed his administration's commitment to revitalizing American leadership, defense readiness, and strategic dominance in global affairs.
Mr. Su, who also serves as the founder of Artisan Business Group and the America First Asia Institute, has been a vocal advocate for rebuilding America's shipbuilding capabilities, advancing maritime technology, and strengthening the country's role in the Indo-Pacific region. His correspondence to the White House emphasized the critical importance of reshoring strategic industries and reaffirming America's commitment to economic and military leadership in the 21st century.
President Trump responded, stating:
"Every day, my Administration is working to ensure that our foreign policy serves the interests of our citizens, promotes our values, and strengthens our Nation. When America is strong, the world is a safer place, and the American people are more secure, prosperous, and free."
As HTCO continues to expand its mission of innovation and sustainability in global maritime logistics, Mr. Su's leadership supports the Company's commitment to enhancing industrial capabilities and pursuing innovative shipping solutions in line with broader industry and economic goals.
"We are honored to see our Director's views recognized at the highest level," said Mr. Shixuan He, CEO of High-Trend International Group. "Brian Su's commitment to American enterprise, technological innovation, and global cooperation reflects the core mission of HTCO as we lead the transformation of the ocean shipping industry with cleaner, smarter, and more secure maritime technologies."
HTCO is actively developing partnerships and pilot projects to introduce advanced clean energy propulsion systems and intelligent logistics platforms across its global network. With growing geopolitical uncertainties and increased calls for supply chain resilience, the Company is positioning itself as a strategic player in reshoring maritime manufacturing and leading technological modernization of ocean freight infrastructure.
About High-Trend International Group (HTCO)
High-Trend International Group is a publicly traded global shipping and logistics company (NASDAQ: HTCO) focused on sustainable maritime solutions, infrastructure development, and international trade facilitation. With a presence in key global markets, the Company is committed to driving innovation, operational excellence, and long-term shareholder value in the rapidly evolving ocean transportation sector.
Forward-Looking Statements
This press release includes forward-looking statements under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those anticipated. For a discussion of the risks and uncertainties that could affect our future results, refer to the Company's filings with the U.S. Securities and Exchange Commission.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
High-Trend International Group (NASDAQ: HTCO) Welcomes President Trump's Support as Board Member Brian Su Advocates for U.S. Maritime Innovation and Global Leadership
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
